I was disappointed to learn today that the FORTIS-M trial, a study of 720 patients with previously treated advanced NSCLC randomized to receive talactoferrin-alpha (TLF) or placebo, was reported as being negative in a press release late yesterday.

Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?".  Our